TransMedics Group, Inc. (TMDX) – What Are Researchers Thinking About This Stock?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned a consensus rating of “Hold” from the twelve research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $115.60.

TMDX has been the topic of a number of recent research reports. Canaccord Genuity Group decreased their price objective on TransMedics Group from $95.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, October 13th. UBS Group lowered their price target on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Finally, Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a research note on Friday, September 11th.

Insider Buying and Selling

In other news, Director David Weill acquired 1,336 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was acquired at an average price of $81.63 per share, with a total value of $109,057.68. Following the completion of the purchase, the director directly owned 16,392 shares in the company, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TMDX. Braidwell LP lifted its stake in TransMedics Group by 85.1% in the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock worth $40,497,000 after acquiring an additional 280,324 shares during the period. Deutsche Bank AG purchased a new position in TransMedics Group during the 2nd quarter valued at about $14,415,000. Bank of New York Mellon Corp purchased a new position in TransMedics Group during the 2nd quarter valued at about $12,869,000. Trek Financial LLC bought a new stake in shares of TransMedics Group in the 3rd quarter valued at about $11,989,000. Finally, Legal & General Group Plc bought a new stake in shares of TransMedics Group in the 2nd quarter valued at about $5,286,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Up 1.0%

TMDX stock opened at $67.34 on Friday. The firm has a fifty day moving average price of $80.57 and a 200 day moving average price of $94.17. TransMedics Group has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The firm has a market cap of $2.33 billion, a PE ratio of 33.84, a price-to-earnings-growth ratio of 0.92 and a beta of 2.14.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. During the same period in the previous year, the company earned $0.92 EPS. TransMedics Group’s revenue for the quarter was up 20.7% compared to the same quarter last year. Sell-side analysts anticipate that TransMedics Group will post 1.46 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.